Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7136057 | 0.98 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL7142195 | 0.98 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL26455065 | 0.95 | — | — | |
| SCHEMBL25676488 | 0.95 | — | — | |
| Furan SCHEMBL8509160 | 0.84 | — | — | |
| SCHEMBL16544810 | 0.84 | — | — | |
| SCHEMBL13677376 | 0.80 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL14949135 | 0.77 | — | — | |
| SCHEMBL15339698 | 0.77 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL27008513 | 0.75 | ALDH1A1 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180051042-A1 | METHODS FOR FORMING SATURATED (HETERO)CYCLIC BORYLATED HYDROCARBONS AND RELATED COMPOUNDS | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2018-02-22 | — | — | US | disclosed |
| US-20180051042-A1 | METHODS FOR FORMING SATURATED (HETERO)CYCLIC BORYLATED HYDROCARBONS AND RELATED COMPOUNDS | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2018-02-22 | — | — | US | disclosed |
| EP-3125277-A1 | SEMICONDUCTOR ELEMENT AND INSULATING-LAYER-FORMING COMPOSITION | FUJIFILM Corporation (JP) | 2017-02-01 | — | — | EP | disclosed |
| EP-0670831-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-13 | — | — | EP | disclosed |
| WO-1995009159-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180051042-A1 | METHODS FOR FORMING SATURATED (HETERO)CYCLIC BORYLATED HYDROCARBONS AND RELATED COMPOUNDS | BRS3, CBR3, C9 | ALDH1A1 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.